MannKind Corp - Asset Resilience Ratio
MannKind Corp (MNKD) has an Asset Resilience Ratio of 26.82% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MannKind Corp debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2024)
This chart shows how MannKind Corp's Asset Resilience Ratio has changed over time. See MannKind Corp (MNKD) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MannKind Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of MannKind Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $132.64 Million | 26.82% |
| Total Liquid Assets | $132.64 Million | 26.82% |
Asset Resilience Insights
- Very High Liquidity: MannKind Corp maintains exceptional liquid asset reserves at 26.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MannKind Corp Industry Peers by Asset Resilience Ratio
Compare MannKind Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for MannKind Corp (2002–2024)
The table below shows the annual Asset Resilience Ratio data for MannKind Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 38.32% | $150.92 Million | $393.84 Million | +26.40pp |
| 2023-12-31 | 11.91% | $56.62 Million | $475.20 Million | -22.32pp |
| 2022-12-31 | 34.23% | $101.08 Million | $295.28 Million | +9.34pp |
| 2021-12-31 | 24.89% | $79.93 Million | $321.16 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $108.61 Million | -- |
| 2019-12-31 | 21.32% | $19.98 Million | $93.72 Million | +15.63pp |
| 2017-12-31 | 5.69% | $4.81 Million | $84.58 Million | +5.36pp |
| 2016-12-31 | 0.33% | $350.00K | $107.06 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $126.41 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $394.44 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $258.65 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $251.31 Million | -- |
| 2011-12-31 | 0.26% | $515.00K | $199.55 Million | -1.32pp |
| 2010-12-31 | 1.58% | $4.37 Million | $277.26 Million | +0.58pp |
| 2009-12-31 | 1.00% | $2.48 Million | $247.40 Million | -5.67pp |
| 2008-12-31 | 6.67% | $18.84 Million | $282.46 Million | -14.99pp |
| 2006-12-31 | 21.66% | $116.92 Million | $539.74 Million | -17.57pp |
| 2005-12-31 | 39.23% | $89.60 Million | $228.37 Million | +32.17pp |
| 2004-12-31 | 7.06% | $11.55 Million | $163.48 Million | +5.61pp |
| 2003-12-31 | 1.45% | $1.82 Million | $125.88 Million | -9.18pp |
| 2002-12-31 | 10.63% | $11.13 Million | $104.77 Million | -- |
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. It offers Afrezza inhalation powder, an inhaled insulin used to improve… Read more